TrialX, a NYC-based life sciences technology company has launched Covid Labs, an open platform made up of computer scientists, informaticians, data scientists and designers that are banding together across organizations to solve unique challenges posed by the COVID-19 pandemic. The initiative aims to enable individuals, healthcare agencies, life sciences companies and governments to leverage the power of data, web and mobile technologies to understand and tackle this global crisis.
Dr. Sharib Khan, Co-founder and CEO of TrialX, who kickstarted this initiative mentioned, “As we face a once in a lifetime pandemic, the speed at which the COVID-19 has spread globally, requires the same agility in how we respond to it. Whether it be social distancing to ‘flatten the curve’, or staying up all night, to hack open data sets or re-package existing code, the crisis is a rallying cry for all of us to pitch in.”
In the spirit of “hacking” the pandemic, the lab has already launched several projects including CovidClinicalTrials.com, a global clinical trials tracker displaying a dashboard of all ongoing/planned COVID clinical trials and new treatments and vaccines being investigated by sponsors and research universities. The website provides resources for patients to find and contact research centers near them. The lab has also created a cross-platform symptom tracker app based on Apple’s ResearchKit and Android ResearchDroid to allow investigators and researchers to launch research studies for tracking symptoms related to COVID-19. To increase awareness, the lab hosted a discussion on living with Covid-19 on the CureTalks online radio show that features leading experts and patient advocates.
The lab has an open invite to individuals with a passion for life sciences, public health, data and technology to leverage their skills to hack this pandemic.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.